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ABSTRACT 
Ketorolac tromethamine is a drug with narrow therapeutic index and short biological half-life. This study was aimed at developing 
and optimizing proniosomal formulation of ketorolac tromethamine in order to improve its bioavailability. The prepared 
proniosomal gel formulations were evaluated and the effect of the varying composition of non ionic surfactant and cholesterol in 
various formulations were studied, such as vesicle shape, zeta potential, entrapment efficiency, and in- vitro drug release study. The 
presence of cholesterol made the proniosomes more stable with high drug entrapment efficiency and retention properties. The 
highest entrapment efficiency was observed with sodium cholate 88.17 ± 0.95 as compared to those formulation prepared with 
span60 and with sodium deoxycholate. Formulation F1 (LCI-I), zeta potential value was observed -20.0 mV, which is a measure of 
net charge of proniosomes which made them stable, by preventing aggregation. Formulation   F1 which prepared by sodium cholate,  
showed highest drug release of 94.048 % after 24 hrs as compared to formulation F6 (LDCI-3) and F9 (LSI-3) which were prepared 
by sodium deoxycholate and sapn60 showed lowest drug release of  76.35% and 69.12%. 
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INTRODUCTION: 
Development of a new drug molecule is expensive and 
time consuming. Improving safety efficacy ratio of “old” 
drugs has been attempted using therapeutic drug 
monitoring (TDM) of formulation based on novel drug 
delivery systems. Proniosomes are based on dry 
formulation of water soluble carriers that are coated with 
surfactant. It forms niosomal dispersion immediately 
during the rehydration to before use on agitation in hot 
aqueous media within minutes
1
. Proniosomes are 
physically stable during the storage and transport. Drug 
encapsulated in the vesicular structure of proniosomes 
prolong the existence of drug in the systematic 
circulation and enhances the penetration into target 
tissue and reduce toxicity. Due to the limited amount of 
water present, these systems behave as viscous phases. 
When compared with conventional formulations, 
generally show a better control of blood levels, a 
reduced incidence of systemic toxicity, no hepatic first-
pass metabolism and a higher compliance 
2,3
. These 
‘proniosomes’ minimize problems associated with 
niosome base formulation such as physical stability like 
aggregation, fusion and leaking, and provide additional 
convenience in transportation, distribution, storage, and 
dosing. The focus of this research work is to bring out 
different aspects related to proniosomes preparation, 
characterization, entrapment efficiency, in vitro drug 
release and in vitro permeation studies. 
METHOD OF PREPARATION: 
The proniosomes were prepared by rotatory flask 
method by dissolving cholesterol and various types of 
surfactants (span60, sodium deoxycholate and sodium 
cholate) in different concentration in alcohol and thin 
film was formed along the sides of the flask by 
continuous vortexing. Drug was dissolved in 10ml of 
phosphate buffer saline (PBS) pH.7.4 and added to the 
thin film and then sonicated for 5 min. The proniosomal 
suspensions were formed, and then these suspensions 
kept at 4
o
C. 
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Table 1: Optimization of Proniosomal Formulation 
 
 
 
 
 
 
 
 
C: Sodium Cholate, D: Sodium Deoxycholate, I: Isopropanol L: Lipid, S: Span60 
Characterization  
Determination of Zeta Potential: The zeta potential of 
the selected batch of proniosomal formulation was 
determined at 25ºC using Zetasizer (Malvern 
Instruments). 4 Proniosomal suspension was diluted 100 
times with double-distilled water and voltage was set at 
50 or 100 V and electrodes were placed in dispersion for 
the measurement of zeta potential. 
Scanning Electron Microscope: The sizes of the 
vesicles were measured by scanning electron 
microscopy 5. Small amount of proniosomal suspension 
was placed on the specimen stub, coated with carbon 
and then with gold vapor using Hitachi vacuum 
evaporator. The samples were examined under scanning 
electron microscope, and then photographed. 
Entrapment Efficiency: The entrapment efficiency was 
determined after separating the unentrapped drug. 
Proniosomes (100mg) was hydrated with 10 ml of 
phosphate buffer saline (pH 7.4) manual shaking for 5 
minutes, to form PN dispersion. For the separation of 
unentrapped drug the PN dispersion was centrifuged at 
15000 rpm for 30 minutes at 20
0
C and analyzed by UV 
spectroscopy at 322 nm. The entrapment efficiency was 
calculated using the formula: 
                          
  
                                      
           
       
In vitro Drug Release: The release of Ketorolac 
Tromethamine from proniosomal gel was determined 
using membrane diffusion technique. The proniosomal 
gel equivalent to 1mg of Ketorolac Tromethamine was 
placed in a dialysis bag tied to glass tube acting as a 
donor compartment. The glass tube was placed in a 
beaker containing 50ml of phosphate buffer (pH7.4), 
acting as a receptor compartment. The whole assembly 
was fixed in such a way that the lower end of tube 
containing gel was just touching the surface of diffusion 
medium. The temperature of receptor medium was 
maintained at 37 ± 05°C and was agitated at the speed of 
100 rpm using magnetic stirrer. Aliquots of 3ml sample 
were withdrawn periodically and after each withdrawal 
same volume of medium was replaced. The collected 
sample was analyzed by UV spectrophotometer using 
phosphate buffer (pH 7.4) as blank. 
RESULTS AND DISCUSSION:  
Determination of Zeta potential: - The formulation 
F1, which was subjected to Zeta potential analysis, had a 
zeta value of -20.0 mV, which is a measure of net 
charge of proniosomes. High surface charge provides 
sufficient electrostatic repulsion between the vesicles, 
which made them stable, by preventing aggregation. 
Negative charge leads to rapid blood clearance.
 
 
Figure 1: Zeta Potential Analysis 
By Scanning Electron Microscope (SEM): Scanning 
electron microscopy for the selected formulation F1was 
carried out. The results are shown in the following SEM 
photograph. 
Batch Formulations Surfactant: Lipid: 
Alcohol Ratio (w/w) 
PBS pH 
7.4 (ml) 
F1 LCI-1 2.1:0.3:9 10 
F2 LCI-2 1.71:0.3:7 10 
F3 LCI-3 0.9:0.3:4 10 
F4 LDCI-1 2.1:0.3:9 10 
F5 LDCI-2 1.71:0.3:7 10 
F6 LDCI-3 0.9:0.3:4 10 
F7 LSI-1 2.1:0.3:9 10 
F8 LSI-2 1.71:0.3:7 10 
F9 LSI-3 0.9:0.3:4 10 
Farooqui et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2017; 7(7):38-40                       
ISSN: 2250-1177                                                                                [40]                                                                             CODEN (USA): JDDTAO 
 
Figure 2: Proniosomes observed under SEM 
Entrapment Efficiency: Entrapment efficiency is the 
percentage fraction of the total drug incorporated into 
the Proniosomes. As shown in figure no.03. Formulation 
LCI-1 (88.17 ± 0.95) exhibited very high entrapment 
efficiency. This could be explained on the basis that the 
highly lipophilic portion of the drug is expected to be 
housed almost completely within the lipid bilayer of the 
proniosomes.
 
 
Figure 3: Entrapment Efficiency of Proniosomal Suspension 
 
Figure 4: % Cumulative Drug Release of Gel Formulations 
In Vitro Drug Release of Proniosomal Gel: 
Formulation F1 showed highest drug release of 94.011 
% in 24 hrs and formulation F9 showed lowest drug 
release of 71.789 % in 16 hrs (Figure 4). After 
incorporation of proniosomal vesicles into gel base they 
show significant delayed in in-vitro drug release in 24 
hours as compared to proniosomal suspension 
CONCLUSION: 
The results of the present investigation showed that the 
problems associated with the transdermal delivery of KT 
could be overcome by incorporating it into the new PN 
drug carrier, proniosomes. Among the nine PN 
formulations developed for transdermal delivery of KT, 
LCI-1 (F1) showed promising higher entrapment 
efficiency, showed highest drug release of 94.048 % 
after 24 hrs as compared to formulation F6 (LDCI-3) 
and F9 (LSI-3) which were prepared by sodium 
deoxycholate and sapn60 showed lowest drug release of  
76.35% and 69.12%. 
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